Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 4Phase 1/2 3Phase 3 2

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Lymphoma 7Lymphoma, Large B-Cell, Diffuse 5Glioblastoma 5Breast Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Carcinoma, Non-Small-Cell Lung 4Multiple Myeloma 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Gliosarcoma 3Small Cell Lung Carcinoma 2Sarcoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Erythroblastic, Acute 2Leukemia 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Graft vs Host Disease 2Glioma 2Carcinoma, Renal Cell 2

Interventions

Dexamethasone 132Lenalidomide 58Bortezomib 56Calcium Dobesilate 44Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9isatuximab 9Mycophenolic Acid 9pembrolizumab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × Vorinostat × Clear all
NCT01502085 2026-04-03

RZD

Hackensack Meridian Health

Phase 1/2 Completed
25 enrolled 5 charts
Plasma cell

Multiple Myeloma

NCT01297764 2026-03-23

QUAD

Hackensack Meridian Health

Phase 1/2 Active not recruiting
17 enrolled
Plasma cell

Multiple Myeloma

NCT00857324 2017-09-06

Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients

University of Turin, Italy

Phase 1/2 Terminated
18 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡